Where is PhRMA in the mifepristone debate?
PhRMA hasn’t put out a press release about a Texas judge suspending approval for mifepristone, even though the ruling could destabilize the FDA.
WASHINGTON — A judge’s decision to suspend the Food and Drug Administration’s approval of an abortion pill could have massive impacts for the pharmaceutical industry, but its largest lobbying association is staying on the sidelines.
PhRMA, which is the top-spending lobbying group in the health care sector and is known to be litigious itself, still hasn’t put out a press release on the decision made by a judge in Texas on Friday — despite the possibility that the decision could destabilize the sanctity of the FDA approval process entirely.
What's Your Reaction?
